NASDAQ
07.08.26 | 22:00
7,270 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.07. | Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday | 1 | The Motley Fool | ||
| 24.07. | This Shattuck Labs Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday | 1 | Benzinga.com | ||
| 24.07. | JPMorgan reiterates Shattuck Labs stock rating on DR3 program | 4 | Investing.com | ||
| 11.06. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Shattuck Labs drops 6%, prices $75M share raise at $4 per share | 1 | Seeking Alpha | ||
| 10.06. | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | 292 | AFX News | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| 10.06. | Shattuck Labs prices $75M public offering at $4 per share | 1 | Investing.com | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 10.06. | Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs commences public offering of common stock | 2 | Investing.com | ||
| 09.06. | Shattuck Labs launches proposed public offering of common stock | 1 | Seeking Alpha | ||
| 09.06. | Shattuck Labs, Inc. Announces Proposed Public Offering | 1 | GlobeNewswire (USA) | ||
| 09.06. | Shattuck Labs receives $54.9M from warrant exercises | 1 | Investing.com | ||
| 09.06. | Shattuck Labs secures $54.9M from warrant exercises, extends cash runway into 2029 | 1 | Seeking Alpha | ||
| 09.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update | 204 | GlobeNewswire (Europe) | AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class... ► Artikel lesen | |
| 08.06. | Why Is Shattuck Labs Stock Trading Lower On Monday? | 1 | Benzinga.com | ||
| 08.06. | Shattuck Labs reports phase 1 data for DR3 blocking antibody | 1 | Investing.com | ||
| 08.06. | Shattuck Labs, Inc.: Shattuck Labs Announces Phase 1 Results for SL-325 | 693 | GlobeNewswire (Europe) | Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of... ► Artikel lesen | |
| 05.06. | Shattuck Labs to present phase 1 data for SL-325 on Monday | 3 | Investing.com | ||
| 05.06. | Shattuck Labs: Vorstellung von Phase-1-Studiendaten zu SL-325 am Montag | 1 | Investing.com Deutsch | ||
| 05.06. | Shattuck Labs, Inc.: Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8 | 2 | GlobeNewswire (USA) |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,291 | +0,04 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| VIVOSIM LABS | 0,468 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,281 | +2,18 % | Der Weg zur Klinik: Wie Finanzierung Biotech-Erfolge ermöglicht | ||
| SAREPTA THERAPEUTICS | 14,720 | +1,38 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| ARROWHEAD PHARMACEUTICALS | 74,84 | -1,29 % | Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events | ||
| ONCO-INNOVATIONS | 0,400 | -0,99 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| REVOLUTION MEDICINES | 176,85 | -0,42 % | Revolution Medicines: Steht der nächste Durchbruch bevor? Aktie auf Rekordhoch! | Die Biotech-Gesellschaft hat im Frühjahr mit einem Spätphasen-Erfolg zur Behandlung von zuvor therapiertem Bauchspeicheldrüsenkrebs für Furore gesorgt. Noch verfügt der Hoffnungsträger über keine offizielle... ► Artikel lesen | |
| TRAWS PHARMA | 0,543 | +2,05 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 5,600 | -4,01 % | Verastem outlines October VS-7375 response-rate update while targeting LGSOC self-sustainability by end of 2026 | ||
| UNIQURE | 39,900 | -0,62 % | uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update | ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~
~ Topline four-year data from the Phase I/II study of AMT-130 expected... ► Artikel lesen | |
| ZAI LAB LTD ADR | 20,600 | +1,98 % | Citi Raises Zai Lab Limited TP to USD45, Expects China Business to Stabilize in 2H26 | ||
| TRINITY BIOTECH | 12,500 | +0,56 % | Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology | - Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,830 | -0,14 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| XBIOTECH | 1,960 | 0,00 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 7,270 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.